GZ17-6.02 Interacts With [MEK1/2 and B-RAF Inhibitors] to Kill Melanoma Cells

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Cutaneous melanoma with B-RAF V600E mutation is a target for kinase inhibitors.
• Acquired resistance to therapies like vemurafenib remains a clinical challenge.
• Understanding drug interactions is crucial for optimizing melanoma treatment.

Purpose of the Study:

• To define the lethal interaction between GZ17-6.02 and trametinib/dabrafenib in B-RAF V600E melanoma.
• To investigate the molecular mechanisms underlying this drug combination's efficacy.
• To assess the combination's activity in vemurafenib-resistant melanoma models.

Main Methods:

• Utilized patient-derived xenograft (PDX) isolates of cutaneous melanoma.
• Assessed drug interactions, phosphorylation status of key signaling proteins (ATM, AMPK, eIF2α, JAK2, STAT3, STAT5, mTOR, ULK1).
• Performed gene knockdown studies and analyzed expression of CD95, FAS-L, PD-L1, and MHCA.

Main Results:

• GZ17-6.02 demonstrated additive lethality with trametinib/dabrafenib in B-RAF V600E melanoma cells.
• The combination prolonged specific phosphorylation events and altered signaling pathways, including mTOR and JAK/STAT.
• GZ17-6.02 increased CD95/FAS-L expression and, with the combination, reduced PD-L1 and increased MHCA via HDAC degradation.
• Knockdown of key proteins (e.g., eIF2α, ATM, CD95) and expression of activated kinases affected drug efficacy.

Conclusions:

• GZ17-6.02 exhibits additive lethality with trametinib/dabrafenib in B-RAF V600E melanoma, irrespective of vemurafenib resistance.
• The combination targets critical cell survival and death pathways.
• Findings support the clinical investigation of GZ17-6.02 combined with trametinib/dabrafenib for B-RAF V600E melanoma treatment.